Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population

被引:8
|
作者
Mutawi, Thuraya M. [1 ]
Zedan, Mohamed M. [2 ]
Yahya, Raida S. [1 ]
Zakria, Mahmoud M. [3 ]
El-Sawi, Mamdouh R. [4 ]
Gaedigk, Andrea [5 ,6 ]
机构
[1] Mansoura Univ, Children Hosp, Dept Labs, Fac Med, Mansoura 35516, Egypt
[2] Mansoura Univ, Dept Pediat, Fac Med, Mansoura 35516, Egypt
[3] Mansoura Univ, Urol & Nephrol Ctr, Fac Sci, Mansoura 35516, Egypt
[4] Mansoura Univ, Div Physiol, Dept Zool, Fac Sci, Mansoura 35516, Egypt
[5] Univ Missouri Kansas City, Childrens Mercy Kansas City, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA
[6] Univ Missouri Kansas City, Sch Med, Kansas City, MO 64108 USA
关键词
genotype; phenotype Egyptian population; PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; HUMAN CYTOCHROME-P450 2D6; POOR METABOLIZERS; CPIC GUIDELINE; CYP3A4-ASTERISK-22; POLYMORPHISMS; ALLELES; DUPLICATION; PHENOTYPE; VARIANTS;
D O I
10.2217/pgs-2020-0140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: This study investigated major allelic variants of CYP2D6, CYP3A4 and CYP3A5 in Egyptians, an Arabic population for which there is little information regarding these important pharmacogenes. Patients & methods: CYP2D6*2, *4, *5, *10, *41 and gene copy number variation, as well as CYP3A4*22 and CYP3A5*3 were determined with commercially available TaqMan assays in 145 healthy study participants. Results: The CYP2D6 alleles identified suggest that the prevalence of poor metabolizers is low as none were found among the 145 subjects investigated. The frequency for CYP3A5 nonexpressers was 74.5% and the CYP3A4*22 allele frequency was low at 2.0%. Conclusion: These preliminary findings indicate that pharmacogene variation in Egyptians is different from those of other Middle Eastern/Arabic populations and warrants further investigation.
引用
收藏
页码:323 / 334
页数:12
相关论文
共 50 条
  • [21] Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population
    Williams, Michael L.
    Kannankeril, Prince J.
    Breeyear, Joseph H.
    Edwards, Todd L.
    Van Driest, Sara L.
    Choi, Leena
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (04) : 896 - 908
  • [22] Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques
    Uno, Yasuhiro
    Matsushita, Akinori
    Osada, Naoki
    Uehara, Shotaro
    Kohara, Sakae
    Nagata, Ryoichi
    Fukuzaki, Koichiro
    Utoh, Masahiro
    Murayama, Norie
    Yamazaki, Hiroshi
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (02) : 209 - 214
  • [23] Hydroxychloroquine is metabolized by CYP2D6, CYP3A4 and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A4 in vitro
    Paludetto, M.
    Kurkela, M.
    Kahma, H.
    Backman, J.
    Niemi, M.
    Filppula, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S78 - S78
  • [24] Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes
    Fohner, Alison
    Muzquiz, LeeAnna I.
    Austin, Melissa A.
    Gaedigk, Andrea
    Gordon, Adam
    Thornton, Timothy
    Rieder, Mark J.
    Pershouse, Mark A.
    Putnam, Elizabeth A.
    Howlett, Kevin
    Beatty, Patrick
    Thummel, Kenneth E.
    Woodahl, Erica L.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (08): : 403 - 414
  • [25] Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients
    Gervasini, G.
    García-Martín, E.
    Ladero, J. M.
    Pizarro, R.
    Sastre, J.
    Martínez, C.
    García, M.
    Díaz-Rubio, M.
    Agúndez, J. A. G.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 : 54 - 54
  • [26] Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients
    Gervasini, Guillermo
    Garcia-Martin, Elena
    Ladero, Jose M.
    Pizarro, Rosa
    Sastre, Javier
    Martinez, Carmen
    Garcia, Monserrat
    Diaz-Rubio, Manuel
    Agundez, Jose A. G.
    BMC CANCER, 2007, 7 (1)
  • [27] Comparative drug metabolism by CYP3A4 and CYP3A5
    Huang, WL
    Lin, YS
    Dai, Y
    Totah, RA
    Calamia, JC
    Thummel, KE
    DRUG METABOLISM REVIEWS, 2003, 35 : 187 - 187
  • [28] Statin regulation of CYP3A4 and CYP3A5 expression
    Vieira Willrich, Maria Alice
    Hirata, Mario Hiroyuki
    Crespo Hirata, Rosario Dominguez
    PHARMACOGENOMICS, 2009, 10 (06) : 1017 - 1024
  • [29] Comparison of Paeoniflorin and Albiflorin on Human CYP3A4 and CYP2D6
    Gao, Li-Na
    Zhang, Ye
    Cui, Yuan-Lu
    Akinyi, Olunga Mary
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
  • [30] Influence of CYP3A4 and CYP2D6 inhibition on fesoterodine treatment
    Sachse, R
    Cawello, W
    Horstmann, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1186 - 1186